Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Everest Medicines, Innoviva - LARVOL DELTA

Occurrence and assessment of antibiotic resistance and virulence of Enterococcus spp. strains isolated from fecal samples of wild animals. (PubMed, Sci Rep) - "The frequency of occurrence of vancomycin-resistant enterococci (VRE) phenotypes, high-level streptomycin resistance (HLSR), high-level gentamicin resistance (HLGR), and high-level aminoglycoside resistance (HLAR) was also determined...The majority of strains exhibited resistance to eravacycline, while the least resistance was observed against ampicillin...The virulence factors were present in the tested strains, and the most frequently detected gene was agg encoding aggregation substance. We have provided evidence that healthy wild animals can be reservoirs of pathogenic Enterococcus strains, including MDR strains and with many VGs, which can be transmitted to humans."

Journal • Infectious Disease

An overview of potential combinations therapies with ceftriaxone as a treatment for gonorrhea. (PubMed, Expert Rev Anti Infect Ther) - "Of these 16 antimicrobials, we reject antimicrobials such as fosfomycin due to poor clinical efficacy and tigecycline due to its considerably longer half-life which would likely select for tetracycline resistance. The most promising agents for combination with ceftriaxone are zoliflodacin, delafloxacin, sitafloxacin, eravacycline and possibly gepotidacin and gentamicin. Clinical studies should be conducted to evaluate the efficacy of these combinations on the eradication of N. gonorrhoeae and their impact on AMR in N. gonorrhoeae and other bacterial species."

Journal • Review • Infectious Disease

Emergence and dissemination of multidrug-resistant Klebsiella pneumoniae harboring the novel tmexCD-toprJ RND efflux pump operon. (PubMed, Front Cell Infect Microbiol) - "Tigecycline and eravacycline, have been considered a last-resort therapeutic against MDR Enterobacteriaceae. The emergence of tmexCD-toprJ-positive CRKP in lung transplant patients highlights the potential for rapid nosocomial dissemination and reduced treatment efficacy of last-line antimicrobials. Our findings emphasize the need for enhanced genomic surveillance, infection control measures, and alternative therapeutic strategies to combat the spread of tmexCD-toprJ-mediated resistance in clinical settings."

Journal • Infectious Disease • Pneumonia • Transplantation

Emergence of an XDR Klebsiella pneumoniae ST5491 strain co-harboring NDM-5, MCR-1.1, tmexCD1-toprJ1, and a novel plasmid carrying CTX-M-15. (PubMed, Front Microbiol) - "KP09 exhibited broad-spectrum resistance to carbapenems, colistin, eravacycline, and tigecycline, and only remained susceptible to cefiderocol. This study provides critical information on the genetic mechanisms that drive AMR in K. pneumoniae, including the identification of a novel bla CTX-M-15 encoding IncFIA/IncFII/IncQ1 hybrid plasmid and the emergence of the ST5491 strain. Understanding the genetic basis of resistance is essential to inform public health interventions and mitigate the impact of AMR."

Journal • Infectious Disease • Pneumonia

Emergence of transferable tigecycline and eravacycline resistance gene tet(X4) in Escherichia coli isolates from Iran. (PubMed, Sci Rep) - "Tigecycline (TGC) and eravacycline (ERV) are critical last-resort antibiotics used to treat complicated infections caused by extensively drug-resistant Gram-negative bacteria particularly carbapenem- and colistin-resistant Enterobacterales. This study reports, for the first time in Iran, the emergence of transferrable high-level tigecycline/eravacycline resistance gene tet(X4) in E. coli isolates. Given the public health implications, control measures should be implemented to regulate the use of tetracyclines and potentially phenicols in food animals to prevent emergence and further transmission of such superbugs along the animal- environment -human chain."

Journal • Infectious Disease

ANTIBIOTIC SUSCEPTIBILITY OF CLOSTRIDIOIDES DIFFICILE ISOLATES BEFORE AND DURING THE COVID-19 PANDEMIC: EMERGING TREND OF INCREASED MICS IN ANTI-C DIFFICILE AGENTS (DDW 2025) - "Eravacycline (ERA) and omadacycline (OMA) are tetracycline derivatives that have been shown to be promising in treating various bacterial infections...C difficile in vitro susceptibility to ERA, OMA and other current treatment (Vancomycin, Metronidazole and Tigecycline) was determinate by using E-test assay (LIOFICHEM)...However, the Minimum Inhibitory Concentration (MIC) for eravacycline and tigecycline remained lower, in comparison with other antibiotics... This study highlights the in vitro efficacy of tetracycline derivatives, in addition to standard antibiotics, against a diverse collection of C. difficile strains. Although the samples collected after the pandemic showed reduced susceptibility to anti- C. difficile antibiotics, neither disease severity nor recurrence appear to be compromised. These findings support further investigation into tetracycline derivatives as potential therapeutic options for CDI."

Infectious Disease • Novel Coronavirus Disease

The Y58D mutation in rpsJ gene is correlated with tigecycline and eravacycline combined resistance in ST80 vancomycin-resistant Enterococcus faecium isolates. (PubMed, J Glob Antimicrob Resist) - "In this study we correlated the presence of the Y58D mutation in the rpsJ gene with resistance to TGC and ERV in a cluster of VREfm ST80 clinical strains. The Y58D mutation was invariably found in co-presence with tet(L) and tet(M) genes."

Journal

In vitro synergistic effect and mutant prevention concentration of eravacycline alone or in combination with various antibiotics against OXA-48 producing enterobacterales. (PubMed, J Antibiot (Tokyo)) - "The Mutant Prevention Concentrations (MPCs) of eravacycline, tigecycline, levofloxacin, colistin, fosfomycin, meropenem, and tobramycin were evaluated against CRE isolates. This combination therapy may be a viable alternative for treating carbapenemase-producing Enterobacterales bacteria. In addition, eravacycline's lower MPC value suggests it may avoid the emergence of resistant mutant strains in the population."

Journal • Preclinical • Infectious Disease

Hidden in Plain Sight: Identifying Mycobacterium Abscessus as the Covert Cause of Chronic Lung Cavitary Lesions (ATS 2025) - "Description: A 74-year-old male with history of ulcerative colitis, previously treated with Ustekinumab, presented with hemoptysis...Due to suspicion for MAC, the patient was started on Augmentin and doxycycline for two weeks...A peripherally inserted central catheter (PICC) was placed for three months of amikacin and eravacycline infusions, alongside azithromycin and clofazimine...Standard management includes long-term antibiotic regimens and regular assessments, although surgical resection may be required for localized infections. Our case underscores the necessity of including MABC in the differential for patients presenting with cavitary lung lesions to expedite diagnosis and treatment, avoiding the risk for worsening antibiotic resistance."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Nontuberculous Mycobacterial Disease • Oncology • Respiratory Diseases • Ulcerative Colitis • Vasculitis

Eravacycline as a Rescue Therapy for Carbapenem-resistant Gram-negative Bacterial Pneumonia in the Early Post-lung Transplantation Period (ATS 2025) - "It shows promise for treating difficult infections, especially from Stenotrophomonas maltophilia and Burkholderia cepacia. However, treatment should be individualized, and larger studies are needed to validate its efficacy and safety."

Gram negative • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

Species Distribution and Antimicrobial Susceptibility of Diverse Strains Within Burkholderia cepacia Complex. (PubMed, Microb Drug Resist) - "cenocepacia, B. multivorans, and B. contaminans exhibited a susceptibility over 95% to meropenem and sulfamethoxazole-trimethoprim, whereas varying sensitivities were displayed to levofloxacin, ceftazidime, and minocycline (p 95%, and the very major error was <1%, whereas the CA of minocycline and meropenem was <90%. Thus, there are differences in the in vitro antimicrobial susceptibility of different BCC strains, with eravacycline demonstrating lower MIC values compared with tigecycline, minocycline, and omadacycline."

Journal

In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study. (PubMed, BMC Microbiol) - "S. pneumoniae in China exhibits high genetic diversity and significant antibiotic resistance, underscoring the need for continuous surveillance and updated vaccines. New antibiotics remain effective against multidrug-resistant strains, offering potential treatment options in clinical settings."

Clinical • Journal • Preclinical • Infectious Disease • Pneumococcal Infections • Pneumonia

Comparison of disk diffusion, MIC test strip and broth microdilution methods for eravacycline susceptibility testing. (PubMed, Clin Microbiol Infect) - No abstract available

Journal

An Assessment Of Cefiderocol's Synergistic Effects With Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime/avibactam, And Tobramycin Against Carbapenem-Resistant and -Susceptible Pseudomonas aeruginosa. (PubMed, Microb Pathog) - "The findings of this study indicate that combining cefiderocol enhances its synergistic efficacy against both carbapenem-resistant and susceptible P. aeruginosa strains. This suggests that combination therapy could serve as a potential alternative for treating resistant P. aeruginosa infections."

Journal • Critical care • Infectious Disease

A Study to Evaluate the Safety and Tolerability of Eravacycline in Children Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI) (clinicaltrials.gov) - P2 | N=35 | Recruiting | Sponsor: Innoviva Specialty Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis (ChiCTR) - P=N/A | N=9 | Not yet recruiting | Sponsor: SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL

New trial • Infectious Disease

An exploratory study on the efficacy of eravacycline in CRKP infection (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Shanghai tenth People's Hospital; Shanghai tenth People's Hospital

New P4 trial • Infectious Disease • Respiratory Diseases • Urology

Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms. (PubMed, Arch Microbiol) - "Porin modifications reduce the influx of antibiotics, whereas overexpression of efflux pumps, particularly those in the resistance-nodulation-cell division (RND) family, actively expels antibiotics from bacterial cells, significantly lowering intracellular drug concentrations and leading to treatment failure.This review examines the mechanisms of action, resistance profiles, and pharmacokinetic/pharmacodynamic characteristics of newly developed antibiotics designed to combat infections caused by MDR and carbapenem-resistant Gram-negative pathogens. The antibiotics discussed include ceftazidime-avibactam, imipenem-relebactam, ceftolozane-tazobactam, meropenem-vaborbactam, aztreonam-avibactam, delafloxacin, temocillin, plazomicin, cefiderocol, and eravacycline."

Journal • Review • Critical care • Infectious Disease

Colistin, meropenem/vaborbactam, imipenem/relebactam, and eravacycline testing in carbapenem-resistant Gram-negative rods: a comparative evaluation of broth microdilution, gradient test, and VITEK 2 (ESCMID Global 2025) - No abstract available

Gram negative • Infectious Disease

Molecular mechanism of eravacycline resistance in tigecycline-nonsusceptible Acinetobacter baumannii (ESCMID Global 2025) - No abstract available

In-vitro activity of cefiderocol and eravacycline in multidrug-resistant strains of Achromobacter xylosoxidans and Achromobacter denitrificans: implementation of a rapid testing protocol (ESCMID Global 2025) - No abstract available

Preclinical

In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant organisms with different carbapenemase genes: a multicentre study in China, 2021 (ESCMID Global 2025) - No abstract available

Preclinical

A complex case of pelvic bone infection caused by carbapenem-resistant Acinetobacter baumanii successfully treated with eravacycline (ESCMID Global 2025) - No abstract available

Clinical • Infectious Disease • Musculoskeletal Diseases • Orthopedics

Investigation of the in vitro antimicrobial activity of eravacycline alone and in combination with various antibiotics against MDR Acinetobacter baumanni strains. (PubMed, BMC Microbiol) - "Present results reveal essential pharmacodynamic data on eravacycline, a new antibiotic for treating A. baumannii infections, which poses a global threat."

Journal • Preclinical • Infectious Disease

Intraventricular injection of eravacycline in the treatment of carbapenem-resistant Acinetobacter baumannii meningitis: a case report. (PubMed, J Antimicrob Chemother) - No abstract available

Journal • CNS Disorders • Infectious Disease